Absolute 0 8 0 8 B-clinical_variable
neutrophil 9 19 9 19 I-clinical_variable
count 20 25 20 25 I-clinical_variable
( 26 27 26 27 I-clinical_variable
ANC 27 30 27 30 I-clinical_variable
) 30 31 30 31 I-clinical_variable
< 32 33 32 33 O
750 34 37 34 37 B-upper_bound
/ 37 38 37 38 I-upper_bound
μL 38 40 38 40 I-upper_bound

Age 0 3 41 44 B-age
≥ 4 5 45 46 O
10 6 8 47 49 B-lower_bound
years 9 14 50 55 I-lower_bound

Alanine 0 7 56 63 B-clinical_variable
aminotransferase 8 24 64 80 I-clinical_variable
≥ 25 26 81 82 O
5 27 28 83 84 B-lower_bound
× 29 30 85 86 I-lower_bound
upper 31 36 87 92 I-lower_bound
limit 37 42 93 98 I-lower_bound
of 43 45 99 101 I-lower_bound
normal 46 52 102 108 I-lower_bound
( 53 54 109 110 I-lower_bound
ULN 54 57 110 113 I-lower_bound
) 57 58 113 114 I-lower_bound
for 59 62 115 118 O
age 63 66 119 122 B-age

BCR 0 3 123 126 B-cancer
- 3 4 126 127 I-cancer
ABL1 4 8 127 131 I-cancer
- 8 9 131 132 O
rearranged 9 19 132 142 O
( 20 21 143 144 O
Ph+ 21 24 144 147 O
) 24 25 147 148 O
ALL 26 29 149 152 O

CNS3 0 4 153 157 B-cancer
leukemia 5 13 158 166 I-cancer

CRLF2 0 5 167 172 B-treatment
rearrangement 6 19 173 186 I-treatment
with 20 24 187 191 I-treatment
JAK1 25 29 192 196 I-treatment
or 30 32 197 199 I-treatment
JAK2 33 37 200 204 I-treatment
mutation 38 46 205 213 I-treatment
( 47 48 214 215 I-treatment
JAK+ 48 52 215 219 I-treatment
) 52 53 219 220 I-treatment

Completed 0 9 221 230 O
a 10 11 231 232 O
4 12 13 233 234 B-treatment
- 13 14 234 235 I-treatment
drug 14 18 235 239 I-treatment
Induction 19 28 240 249 I-treatment
therapy 29 36 250 257 I-treatment
regimen 37 44 258 265 I-treatment
( 45 46 266 267 O
modified 46 54 267 275 O
aBFM 55 59 276 280 B-treatment
regimen 60 67 281 288 I-treatment
or 68 70 289 291 O
equivalent 71 81 292 302 O
) 81 82 302 303 O
in 83 85 304 306 O
Study 86 91 307 312 O
AALL1131 92 100 313 321 O
or 101 103 322 324 O
as 104 106 325 327 O
the 107 110 328 331 O
institutional 111 124 332 345 O
standard 125 133 346 354 O
of 134 136 355 357 O
care 137 141 358 362 O
for 142 145 363 366 O
HR 146 148 367 369 B-cancer
B 149 150 370 371 I-cancer
- 150 151 371 372 I-cancer
ALL 151 154 372 375 I-cancer
and 155 158 376 379 O
have 159 163 380 384 O
had 164 167 385 388 O
end 168 171 389 392 B-treatment
- 171 172 392 393 I-treatment
Induction 172 181 393 402 I-treatment
minimal 182 189 403 410 I-treatment
residual 190 198 411 419 I-treatment
disease 199 206 420 427 I-treatment
( 207 208 428 429 I-treatment
MRD 208 211 429 432 I-treatment
) 211 212 432 433 I-treatment
assessed 213 221 434 442 O

De 0 2 443 445 B-cancer
novo 3 7 446 450 I-cancer
high 8 12 451 455 I-cancer
- 12 13 455 456 I-cancer
risk 13 17 456 460 I-cancer
( 18 19 461 462 I-cancer
HR 19 21 462 464 I-cancer
) 21 22 464 465 I-cancer
Ph 23 25 466 468 I-cancer
- 25 26 468 469 I-cancer
like 26 30 469 473 I-cancer
B 31 32 474 475 I-cancer
- 32 33 475 476 I-cancer
ALL 33 36 476 479 I-cancer

Direct 0 6 480 486 O
bilirubin 7 16 487 496 B-clinical_variable
≥ 17 18 497 498 O
1.5 19 22 499 502 B-lower_bound
× 23 24 503 504 I-lower_bound
ULN 25 28 505 508 I-lower_bound
( 29 30 509 510 O
may 30 33 510 513 O
be 34 36 514 516 O
assumed 37 44 517 524 O
if 45 47 525 527 O
total 48 53 528 533 O
bilirubin 54 63 534 543 O
is 64 66 544 546 O
below 67 72 547 552 O
ULN 73 76 553 556 O
) 76 77 556 557 O

Eligible 0 8 558 566 O
Ages 9 13 567 571 B-age
in 14 16 572 574 O
Australia 17 26 575 584 O
and 27 30 585 588 O
Canada 31 37 589 595 O
; 37 38 595 596 O
2 39 40 597 598 B-lower_bound
years 41 46 599 604 I-lower_bound
to 47 49 605 607 O
21 50 52 608 610 B-upper_bound
years 53 58 611 616 I-upper_bound

History 0 7 617 624 O
or 8 10 625 627 O
evidence 11 19 628 636 O
of 20 22 637 639 O
cirrhosis 23 32 640 649 B-chronic_disease

Known 0 5 650 655 O
human 6 11 656 661 O
immunodeficiency 12 28 662 678 B-chronic_disease
virus 29 34 679 684 I-chronic_disease
infection 35 44 685 694 I-chronic_disease

Male 0 4 695 699 B-gender

Platelet 0 8 700 708 B-clinical_variable
count 9 14 709 714 I-clinical_variable
< 15 16 715 716 O
75 17 19 717 719 B-upper_bound
× 20 21 720 721 I-upper_bound
10 22 24 722 724 I-upper_bound
^ 24 25 724 725 I-upper_bound
3 25 26 725 726 I-upper_bound
/ 26 27 726 727 I-upper_bound
μL 27 29 727 729 I-upper_bound

Positive 0 8 730 738 O
screen 9 15 739 745 O
for 16 19 746 749 O
hepatitis 20 29 750 759 B-chronic_disease
B 30 31 760 761 I-chronic_disease
or 32 34 762 764 I-chronic_disease
C 35 36 765 766 I-chronic_disease

Systemic 0 8 767 775 B-treatment
steroid 9 16 776 783 I-treatment
pretreatment 17 29 784 796 I-treatment
without 30 37 797 804 O
presteroid 38 48 805 815 O
WBC 49 52 816 819 O
documentation 53 66 820 833 O

Trisomy 0 7 834 841 B-chronic_disease
21 8 10 842 844 I-chronic_disease
( 11 12 845 846 I-chronic_disease
Down 12 16 846 850 I-chronic_disease
syndrome 17 25 851 859 I-chronic_disease
) 25 26 859 860 I-chronic_disease

White 0 5 861 866 B-clinical_variable
blood 6 11 867 872 I-clinical_variable
cell 12 16 873 877 I-clinical_variable
( 17 18 878 879 I-clinical_variable
WBC 18 21 879 882 I-clinical_variable
) 21 22 882 883 I-clinical_variable
≥ 23 24 884 885 O
50 25 27 886 888 B-lower_bound
× 28 29 889 890 I-lower_bound
10 30 32 891 893 I-lower_bound
^ 32 33 893 894 I-lower_bound
3 33 34 894 895 I-lower_bound
/ 34 35 895 896 I-lower_bound
μL 35 37 896 898 I-lower_bound

female 0 6 899 905 B-gender
subjects 7 15 906 914 I-gender
of 16 18 915 917 O
reproductive 19 31 918 930 O
non 32 35 931 934 O
childbearing 36 48 935 947 O
potential 49 58 948 957 O

radioisotope 0 12 958 970 B-clinical_variable
glomerular 13 23 971 981 I-clinical_variable
filtration 24 34 982 992 I-clinical_variable
rate 35 39 993 997 I-clinical_variable
< 40 41 998 999 O
70 42 44 1000 1002 B-upper_bound
mL 45 47 1003 1005 I-upper_bound
/ 47 48 1005 1006 I-upper_bound
min/1.73 48 56 1006 1014 I-upper_bound
m^2 57 60 1015 1018 I-upper_bound

willing 0 7 1019 1026 B-contraception_consent
to 8 10 1027 1029 I-contraception_consent
take 11 15 1030 1034 I-contraception_consent
appropriate 16 27 1035 1046 I-contraception_consent
precautions 28 39 1047 1058 I-contraception_consent
to 40 42 1059 1061 I-contraception_consent
avoid 43 48 1062 1067 I-contraception_consent
pregnancy 49 58 1068 1077 I-contraception_consent
or 59 61 1078 1080 I-contraception_consent
fathering 62 71 1081 1090 I-contraception_consent
a 72 73 1091 1092 I-contraception_consent
child 74 79 1093 1098 I-contraception_consent
for 80 83 1099 1102 O
the 84 87 1103 1106 O
duration 88 96 1107 1115 O
of 97 99 1116 1118 O
study 100 105 1119 1124 O
participation 106 119 1125 1138 O

